跳至主導覽
跳至搜尋
跳過主要內容
國立成功大學 首頁
English
中文
在 國立成功大學 搜尋內容
首頁
概要
研究單位
研究成果
專案
學生論文
設備
獎項
活動
查看斯高帕斯 (Scopus) 概要
顏 亦廷
教授
外科學科
電子郵件
b85401067
gmail
com
h-index
961
引文
16
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
2007
2026
每年研究成果
概覽
指紋
網路
研究成果
(90)
類似的個人檔案
(7)
指紋
查看啟用 Yi-Ting Yen 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Medicine and Dentistry
Video-Assisted Thoracoscopic Surgery
100%
Non Small Cell Lung Cancer
88%
Epithelioma
83%
Segmentectomy
83%
Overall Survival
69%
Epidermal Growth Factor Receptor
66%
Epidermal Growth Factor Receptor Kinase Inhibitor
66%
Lung Cancer
64%
Neoplasm
52%
Progression Free Survival
44%
Thymus Cancer
43%
Computer Assisted Tomography
42%
Mediastinal Tumor
41%
Pneumonectomy
41%
Hazard Ratio
37%
Combination Therapy
36%
Lymphocyte
34%
Prognostic Factor
33%
Cancer Cell
31%
Thymic Carcinoma
29%
Radiomics
27%
Retrospective Cohort Study
27%
Upregulation
27%
Spontaneous Pneumothorax
27%
Retrospective Study
24%
Lobectomy
21%
Neutrophil
20%
Metastatic Carcinoma
20%
Magnetic Resonance Imaging
20%
Primary Tumor
19%
Surgical Technique
19%
Esophageal Squamous Cell Carcinoma
18%
Lung Adenocarcinoma
17%
Postoperative Complication
17%
Disease Free Survival
17%
Lung Tumor
16%
Multidrug Resistant Tuberculosis
16%
Blood Transfusion
16%
Cohort Analysis
16%
Recurrent Disease
15%
Forced Expiratory Volume
15%
Colon Interposition
15%
Lung Function
15%
Chemoradiotherapy
15%
Cancer Growth
15%
Cancer Surgery
15%
Promoter Region
15%
Odds Ratio
14%
Proportional Hazards Model
14%
Chylothorax
13%
Keyphrases
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
43%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
41%
Overall Survival
33%
Hazard Ratio
32%
EGFR mutation
29%
Combination Therapy
29%
Video-assisted Thoracoscopic Surgery
27%
Thymic Epithelial Tumors
27%
Completely Resected
27%
Anatomical Lung Resection
27%
Uniportal
27%
Mediastinal Tumor
27%
Non-small Cell Lung Cancer (NSCLC)
27%
Progression-free Survival
23%
Neutrophil-to-lymphocyte Ratio
20%
Thymic Malignancy
20%
Monotherapy
20%
Thymoma
19%
Chest CT
19%
Survival Benefit
19%
Epidermal Growth Factor Receptor
19%
Tertiary Care Hospital
18%
Non-small Cell Lung Cancer Patients
15%
Confidence Interval
15%
Prognostic Factors
15%
Masaoka Stage
14%
Gastric Pull-up
13%
Complex Segmentectomy
13%
Propensity Matching Analysis
13%
Multi-institutional Study
13%
Total Pharyngolaryngectomy
13%
Surgical Resection
13%
Channel-spatial Attention
13%
False Positive Reduction
13%
Taiwan
13%
Transthoracic Needle Biopsy
13%
Thymic Neuroendocrine Carcinoma
13%
Adenocarcinoma
13%
Thoracoscopic
13%
Pulmonary TB Patients
13%
Delayed Fixation
13%
Single Institution
13%
Spatial Attention Model
13%
Biportal
13%
Partial Gastrectomy
13%
Masaoka Staging
13%
Maxillofacial Fractures
13%
Oronasal
13%
Volume Quantification
13%
Life-threatening Hemoptysis
13%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
82%
Epidermal Growth Factor Receptor
62%
Epidermal Growth Factor Receptor Kinase Inhibitor
61%
Lung Cancer
58%
Neoplasm
42%
Progression Free Survival
39%
Overall Survival
38%
Combination Therapy
31%
Chemotherapy
24%
Malignant Neoplasm
20%
Cancer Growth
20%
Diseases
19%
Chemoradiation Therapy
19%
Monotherapy
16%
Protein Tyrosine Kinase Inhibitor
16%
Bevacizumab
13%
Chemokine
13%
Colony Stimulating Factor 1
13%
Osimertinib
13%
Rapamycin
13%
Esophagus Fistula
13%
Vasculotropin
13%
Primary Tumor
13%
Adenocarcinoma
13%
Cohort Study
13%
Programmed Cell Death
13%
Lung Hemorrhage
13%
Systemic Lupus Erythematosus
13%
Long Untranslated RNA
13%
Esophagus Cancer
13%
Oncolytic Adenovirus
13%
Thrombospondin 1
13%
Programmed Death 1 Ligand 1
13%
Brain Metastasis
13%
Tumor Growth
10%
Tumor Necrosis Factor Receptor Associated Factor 6
9%
Erlotinib
9%
Esophageal Squamous Cell Carcinoma
9%
Biological Marker
8%
Tumor Microenvironment
7%
Transcription Factor
6%
Gefitinib
6%
Pristane
5%
Immune Checkpoint Inhibitor
5%
